Astrazeneca's Enhertu, Orpathys Among 91 Drugs Added to China's National Reimbursement Drug List

MT Newswires Live11-29

Astrazeneca (AZN) confirmed Friday in an emailed statement to MT Newswires that its breast cancer treatment Enhertu and cancer treatment Orpathys have been added to China's National Reimbursement Drug List (NRDL)

The inclusion in the NRDL grants state-run medical insurance coverage to the cancer treatments, starting Jan. 1, 2025, multiple media outlets reported Thursday.

Enhertu is among 91 drugs that will be added to the NRDL, including oncology drugs from drugmakers including Johnson & Johnson (JNJ), Merck (MRK), Bristol Myers (BMY), Roche and Sanofi (SNY), Bloomberg said and added that drugmakers have to accept price cuts, averaging 63%, to secure inclusion on the list.

Zai Lab (ZLAB) said Thursday its AUGTYRO was also included in the NRDL to treat adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2487559242?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-29 21:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2487559242","market":"nz","top_or_hot":-1,"title":"Astrazeneca's Enhertu, Orpathys Among 91 Drugs Added to China's National Reimbursement Drug List","media":"MT Newswires Live","content":"<html><body><p> Astrazeneca (AZN) confirmed Friday in an emailed statement to MT Newswires that its breast cancer treatment Enhertu and cancer treatment Orpathys have been added to China's National Reimbursement Drug List (NRDL)</p><p>The inclusion in the NRDL grants state-run medical insurance coverage to the cancer treatments, starting Jan. 1, 2025, multiple media outlets reported Thursday.</p><p>Enhertu is among 91 drugs that will be added to the NRDL, including oncology drugs from drugmakers including Johnson &amp; Johnson (JNJ), Merck (MRK), Bristol Myers (BMY), Roche and <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> (SNY), Bloomberg said and added that drugmakers have to accept price cuts, averaging 63%, to secure inclusion on the list.</p><p>Zai Lab (ZLAB) said Thursday its AUGTYRO was also included in the NRDL to treat adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Astrazeneca's Enhertu, Orpathys Among 91 Drugs Added to China's National Reimbursement Drug List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstrazeneca's Enhertu, Orpathys Among 91 Drugs Added to China's National Reimbursement Drug List\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-29 21:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Astrazeneca (AZN) confirmed Friday in an emailed statement to MT Newswires that its breast cancer treatment Enhertu and cancer treatment Orpathys have been added to China's National Reimbursement Drug...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0965509010.AUD","symbol_name":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2487559242","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2487559242","pubTimestamp":1732885789,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Astrazeneca  confirmed Friday in an emailed statement to MT Newswires that its breast cancer treatment Enhertu and cancer treatment Orpathys have been added to China's National Reimbursement Drug List The inclusion in the NRDL grants state-run medical insurance coverage to the cancer treatments, starting Jan. 1, 2025, multiple media outlets reported Thursday.Enhertu is among 91 drugs that will be added to the NRDL, including oncology drugs from drugmakers including Johnson & Johnson , Merck , Bristol Myers , Roche and Sanofi , Bloomberg said and added that drugmakers have to accept price cuts, averaging 63%, to secure inclusion on the list.Zai Lab  said Thursday its AUGTYRO was also included in the NRDL to treat adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","BK4548":"巴美列捷福持仓","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BGNE":"百济神州","SNY":"赛诺菲安万特","BMY":"施贵宝","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","JNJ":"强生","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","AZN":"阿斯利康","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","MRK":"默沙东","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","BK4526":"热门中概股","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","NHLD":"National Holdings Corporation","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU1221951129.SGD":"NORDEA 1 STABLE RETURN \"HM\" (SGDHDG) INC","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1732800096.USD":"摩根大通环球收益基金A (irc)","ZLAB":"再鼎医药","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1"},"translate_title":"阿斯利康Enhertu、Orpathys入选中国国家报销药品目录91种药品","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NHLD":1,"BGNE":0.9,"ZLAB":0.9,"SNY":0.9,"MRK":0.9,"JNJ":0.9,"AZN":0.9,"BMY":0.9},"content_text":"Astrazeneca (AZN) confirmed Friday in an emailed statement to MT Newswires that its breast cancer treatment Enhertu and cancer treatment Orpathys have been added to China's National Reimbursement Drug List (NRDL)The inclusion in the NRDL grants state-run medical insurance coverage to the cancer treatments, starting Jan. 1, 2025, multiple media outlets reported Thursday.Enhertu is among 91 drugs that will be added to the NRDL, including oncology drugs from drugmakers including Johnson & Johnson (JNJ), Merck (MRK), Bristol Myers (BMY), Roche and Sanofi (SNY), Bloomberg said and added that drugmakers have to accept price cuts, averaging 63%, to secure inclusion on the list.Zai Lab (ZLAB) said Thursday its AUGTYRO was also included in the NRDL to treat adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2487559242"}